Company Overview: Clarity Pharmaceuticals Limited (ASX:CU6) is an Australia-based clinical-stage radiopharmaceutical company. It is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. This Report covers the Price Action, Technical Indicators Analysis along with the Support Levels, Resistance Levels, and Recommendations on this stock.
1HFY26 Results: In H1’FY26, Clarity remains pre-revenue and reported a loss of AUD 55.6 million, mainly due to higher R&D spending of AUD 50.5 million as clinical activities expanded. The company strengthened its balance sheet through a AUD 203 million institutional placement at AUD 4.20 per share, while total assets increased to AUD 255.7 million as at…
